10-Q: Research Alliance Corp III Nears Business Combination with OHB Pediatrics

Research Alliance Corporation III (RACC) reports on its Q2 2026 financial status, highlighting progress towards its business combination with OHB Pediatrics Ltd. and maintaining a strong cash position.

Summary

• Research Alliance Corporation III (RACC) has filed its Q2 2026 Form 10-Q, detailing its financial condition and operational status.
• The company is actively pursuing a business combination with OHB Pediatrics Ltd. (OHBP), with a Business Combination Agreement signed on July 26, 2026.
• As of June 30, 2026, RACC reported total assets of $76,307,137, primarily consisting of cash and marketable securities held in a Trust Account.
• Total liabilities were $2,305,587, with Class A ordinary shares subject to possible redemption valued at $75,238,468.
• The company reported a net income of $54,050 for the three months ended June 30, 2026, and a net loss of $11,199 for the period from inception (February 19, 2026) to June 30, 2026.
• Significant financing activities included the IPO and private placement, raising substantial capital, with $75,000,000 held in the Trust Account.
• The company is addressing a material weakness in its internal controls related to accounts payable and accrued expenses.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive sentiment, reflecting the progress towards a business combination and the company's financial position, while acknowledging the inherent uncertainties of a SPAC.

Positives

• The company has entered into a definitive Business Combination Agreement with OHB Pediatrics Ltd., marking a significant step towards its business combination.
• A substantial amount of capital is held in the Trust Account ($75,238,468 in marketable securities and $832,812 in cash), providing financial resources for the business combination.
• The company successfully completed its Initial Public Offering (IPO) and a concurrent private placement, raising significant gross proceeds of $75,000,000 and $2,750,000, respectively.
• Interest income earned on marketable securities in the Trust Account was $238,468 for the period.
• The company has a clear plan for its business combination, including domestication to Delaware and renaming to Oak Hill Bio, Inc.

Negatives

• The company has not commenced any operations and does not expect to generate operating revenues until after the completion of its Business Combination.
• A material weakness in internal controls over financial reporting related to accounts payable and accrued expenses has been identified and is being remediated.
• The company's ability to continue as a going concern raises substantial doubt due to a lack of financial resources to sustain operations for a reasonable period beyond one year.
• The financial statements do not include any adjustments that might result from the outcome of uncertainties related to macroeconomic conditions and geopolitical instability.

Risks

• The company must complete a business combination having an aggregate fair market value of at least 80% of the net assets held in the Trust Account.
• There is no assurance that the company will be able to complete a business combination successfully.
• The company is subject to all the risks associated with emerging growth companies.
• Macroeconomic conditions, including geopolitical instability and market volatility, could negatively affect the company's financial position and ability to complete the business combination.
• The company's ability to continue as a going concern is subject to substantial doubt due to a lack of financial resources.
• The effectiveness of the company's disclosure controls and procedures was not effective due to a material weakness in internal controls.

Future Outlook

The company expects to incur increased expenses as a public company and for due diligence related to its business combination. The primary focus is on completing the business combination with OHB Pediatrics Ltd. in the second half of 2026. The company does not expect to generate operating revenues until after the business combination is completed.

Management Comments

• "We have neither engaged in any operations nor generated any revenues to date. Our only activities since inception have been organizational activities and activities related to the IPO."
• "We do not expect to generate any operating revenues until after completion of our initial business combination at the earliest."
• "We expect our expenses to increase substantially as a result of being a public company."
• "We cannot assure you that our plans to raise capital or to complete our initial business combination will be successful."

Industry Context

StockSavvy.ai notes that Research Alliance Corporation III operates as a Special Purpose Acquisition Company (SPAC), a common vehicle for private companies to go public. The current environment for SPACs involves increased scrutiny and a focus on the quality of the target business and the execution of the business combination.

Comparison to Industry Standards

• As a SPAC, direct comparison to operating companies is not applicable. However, the structure and timeline for completing a business combination are standard within the SPAC industry.
• The typical timeframe for a SPAC to complete a business combination is 18-24 months from IPO, and RACC is within this general timeframe.
• The PIPE financing of $55 million is a common component of SPAC transactions to ensure sufficient capital post-combination.
• The $10.00 per share IPO price and redemption value are standard for many SPACs.

Legal Proceedings

• The company is not currently a party to any material litigation or other legal proceedings.
• The company is not aware of any legal proceeding, investigation or claim that has a more than remote possibility of having a material adverse effect on its business, financial condition or results of operations.

Related Party Transactions

• Sponsor purchased Founder Shares and Private Placement Shares.
• Sponsor loaned $300,000 to the company via a promissory note, which was repaid upon IPO.
• Sponsor and affiliates may provide Working Capital Loans, which may be convertible into post-business combination shares.
• Fran Adams, CFO, provides finance and accounting services through van den Boom & Associates, LLC, incurring $51,053 in fees.
• Sponsor and independent directors agreed to vote in favor of the Business Combination Agreement and waive certain anti-dilution protections.

Stakeholder Impact

• Shareholders: Public shareholders have the right to redeem their shares in connection with the business combination. Initial shareholders (Sponsor, directors) have agreed to certain lock-up and voting provisions.
• Creditors: The company has minimal liabilities, and the Sponsor has agreed to indemnify the Trust Account against certain third-party claims.
• Management/Employees: Management is focused on completing the business combination. Compensation related to Founder Shares is contingent on the business combination closing.
• Target Company (OHBP): OHBP shareholders will receive shares of New OHB Common Stock in exchange for their OHBP shares.

Next Steps

• Complete the OHBP Business Combination, expected in the second half of 2026.
• Domestication of the company from Cayman Islands to Delaware, to be renamed Oak Hill Bio, Inc.
• File a resale registration statement for certain shares of New OHB Common Stock within 30 days following the Closing Date.
• Implement remediation plan for material weakness in internal controls.

Key Dates

Recommendation

The company is a SPAC with a pending business combination. While progress has been made with the signing of the Business Combination Agreement and significant capital raised, the inherent risks of SPACs, including the uncertainty of completing the combination and the going concern issues, warrant a hold recommendation. Investors should await the successful completion of the business combination and further operational updates from the combined entity.

Keywords

SPAC, Business Combination, Blank Check Company, Merger, OHB Pediatrics, Trust Account, IPO, Emerging Growth Company